Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Mogroside V is a widely used sweetener, has in vitro AMPK activating effect, it also has anti-inflammatory potential in murine macrophages and a murine ear edema model, and has the potential to protect against LPS-induced airway inflammation in a model of ALI. Mogroside V has antioxidant properties and possesses tumor growth inhibitory activity in pancreatic cancer models.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 67.00 | |
10 mg | In stock | $ 94.00 | |
25 mg | In stock | $ 161.00 | |
50 mg | In stock | $ 274.00 | |
100 mg | In stock | $ 361.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 132.00 |
Description | Mogroside V is a widely used sweetener, has in vitro AMPK activating effect, it also has anti-inflammatory potential in murine macrophages and a murine ear edema model, and has the potential to protect against LPS-induced airway inflammation in a model of ALI. Mogroside V has antioxidant properties and possesses tumor growth inhibitory activity in pancreatic cancer models. |
In vivo | Female BALB/c mice were treated with Mogroside V (2.5, 5 and 10 mg/kg) for 1 h prior to intranasal injection of LPS (10 μg in 50 μl). After 12 h, airway inflammation in the ALI model was determined by the wet/dry weight (W/D) ratio, myeloperoxidase (MPO) activity of lung tissue, leukocyte recruitment and cytokine levels in the bronchoalveolar lavage fluid (BALF). Additionally, lung tissue was examined by histology and western blotting to investigate the changes in pathology and the signalling in the presence and absence of Mogroside V. Mogroside V at 5 and 10 mg/kg inhibited airway inflammation induced by LPS as measured by the decrease in the histological changes (44 and 67.3% reduction in lung injury score, respectively), a 28.9 and 55.3% reduction in lung MPO activity, and inflammatory cell counts, interleukin-1β (IL-1β, 382 and 280 pg/ml, respectively), IL-6 (378 and 232 pg/ml, respectively) and tumor necrosis factor-α (TNF-α, 12.5 and 7.8 ng/ml, respectively) levels in the BALF. Additionally, Mogroside V treatment reduced the activation of cyclooxygenase 2 (COX-2), inducible NO synthase (iNOS), and the nuclear factor (NF)-κB. |
Source |
Molecular Weight | 1287.43 |
Formula | C60H102O29 |
CAS No. | 88901-36-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 100mg/mL
Ethanol: Soluble
DMSO: 10 mM
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Mogroside V 88901-36-4 Chromatin/Epigenetic PI3K/Akt/mTOR signaling AMPK Inhibitor inhibit inhibitor